The genetically diverse viridans group streptococci (VGS) are increasingly recognized as the cause of a variety of human diseases. We used a recently developed multilocus sequence analysis scheme to define the species of 118 unique VGS strains causing bacteremia in patients with cancer; Streptococcus mitis (68 patients) and S. oralis (22 patients) were the most frequently identified strains. Compared with patients infected with non-S. mitis strains, patients infected with S. mitis strains were more likely to have moderate or severe clinical disease (e.g., VGS shock syndrome). Combined with the sequence data, whole-genome analyses showed that S. mitis strains may more precisely be considered as >2 species. Furthermore, we found that multiple S. mitis strains induced disease in neutropenic mice in a dose-dependent fashion. Our data define the prominent clinical effect of the group of organisms currently classified as S. mitis and lay the groundwork for increased understanding of this understudied pathogen.
The genetically diverse viridans group streptococci (VGS) are increasingly recognized as the cause of a variety of human diseases. We used a recently developed multilocus sequence analysis scheme to define the species of 118 unique VGS strains causing bacteremia in patients with cancer; Streptococcus mitis (68 patients) and S. oralis (22 patients) were the most frequently identified strains. Compared with patients infected with non-S. mitis strains, patients infected with S. mitis strains were more likely to have moderate or severe clinical disease (e.g., VGS shock syndrome). Combined with the sequence data, whole-genome analyses showed that S. mitis strains may more precisely be considered as >2 species. Furthermore, we found that multiple S. mitis strains induced disease in neutropenicmice in a dose-dependent fashion. Our data define the prominent clinical effect of the group of organisms currently classified as S. mitis and lay the groundwork for increased understanding of this understudied pathogen.
Entities:
Keywords:
Pitt bacteremia score; Streptococcus mitis; bacteremia; bacteria; cancer; cancer patients; characterization; multilocus sequence analysis; neutropenia; viridans group streptococci
Viridans group streptococci (VGS), a genetically heterogeneous group of bacteria, are the
predominant bacteria in the human oropharynx (). VGS cause a wide range of infections in humans, including bacteremia in
patients with neutropenia, infective endocarditis, and orbital cellulitis (–).
However, despite the substantial clinical effect of VGS, the epidemiology and pathogenesis of these
bacteria are minimally understood ().A major impediment to the study of VGS has been the inability to consistently and accurately
assign VGS strains to specific species, which has resulted in numerous changes in species
designation and classification schemes over time (). From a clinical microbiology laboratory standpoint, automated systems
have considerable limitations in VGS species identification (,). The
problematic nature of VGS species assignment also extends to16S rRNA sequencing, the most widely
used genetic tool for species identification in clinical and research settings (,).Outcomes for patients with VGS bacteremia are highly variable: some patients have minimal
symptoms, and others have a severe infection characterized by hypotension and acute respiratory
distress syndrome (). The severe
infections have been termed VGS shock syndrome (). Numerous studies have examined the species distribution of VGS that
cause bacteremia (,–). However, these studies have found inconsistent results between a
particular VGS species and disease occurrence or clinical severity of infection (,,,,). Moreover, the recently recognized limitations of previously used
techniques of VGS species identification and the low number of clinical cases analyzed preclude
definitive conclusions regarding the relationship between VGS species type and clinical disease
(,,). Thus, we
sought to combine the species identification of a large number of VGS bloodstream isolates, which we
typed by using a recently developed multilocus sequence analysis (MLSA) technique (), with patient-specific clinical data to
determine relationships between VGS species and clinical endpoints.
Materials and Methods
Study Cohort and Data Abstraction
The study cohort comprised patients at MD Anderson Cancer (MDACC) who had VGS isolated from their
blood between July 1, 2011, and December 1, 2012. MDAAC is a 600-bed referral cancer hospital in
Houston, Texas, USA. We used a standardized data collection form to abstract clinical data from the
comprehensive electronic medical records of patients with blood culture results positive for VGS.
Antimicrobial drug resistance was determined in accordance with guidelines of the Clinical and
Laboratory Standards Institute (www.clsi.org/standards/). VGS are known to contaminate blood cultures and to cause
clinically minor, transient bacteremia, and differentiating between contamination and infection is
problematic (). Thus, for the purpose of
this study, we considered that patients without signs or symptoms of infection had clinically minor
bacteremia, even though they may represent cases of blood culture contamination.Severity of infection, as measured by the Pitt bacteremia score, was determined as described
(). Pitt bacteremia scores were not
determined for patients with polymicrobial bacteremia. VGS shock syndrome was defined by using the
accepted definition for septic shock (i.e., hypotension refractory to fluid replacement in the
setting of an infection) (). A focus of
the bloodstream infection was defined as isolation of a VGS species from a nonsterile site (e.g.,
liver abscess) at the same time that VGS were isolated from the blood, with the exception of
infective endocarditis, which was defined according the modified Duke criteria (,). Neutropenia was defined as an absolute neutrophil count of <500
cells/μL.Some patients had signs and symptoms of a lower respiratory infection and x-ray findings
compatible with a pneumonic process that could not be explained (i.e., no known respiratory
pathogens were isolated and no other alternative explanation, e.g., congestive heart failure, was
found). Such patients were defined as having unexplained pulmonary infiltrates. Because VGS are
considered normal flora, isolation of these organisms from a respiratory specimen would not have
been considered clinically meaningful by the clinical microbiology laboratory and thus would not
have been reported. The study protocol was approved by the MDCC institutional review board.
VGS Species Type Determination and Whole-Genome Sequencing
Bacterial isolates were identified as VGS on the basis of the following: presence of
α-hemolysis, gram-positive reaction, coccus morphology arranged in chains, negative catalase
test results, and exclusions of pneumococcus and enterococci by routine biochemical tests (i.e.,
optochin, bile solubility, and pyrrolidonyl arylamidase tests) (). VGS species was determined as described (). In brief, concatenated sequences of 7 housekeeping genes were
used for phylogenetic tree construction in MEGA5 (megasoftware.net/); strains were assigned to VGS
species on the basis of their distance from species type strains (). For whole-genome sequencing of 9 Streptococcusmitis strains and 1 S. oralis strain, we fragmented 3 μg of
genomic DNA to 350 bp (mean fragment size) and prepared barcoded sequencing libraries. The
03/10libraries were sequenced on the HiSeq 2000 sequencing System (Illumina, San Diego, CA, USA) by
using 76-bp, paired-end sequencing. The raw reads in FASTQ format were aligned to the S.
mitis B6 (GenBank accession no. NC_013853.1) and S. pneumoniae TIGR4
(GenBank accession no. NC_003028.3) genomes by using Mosaik (). There was an average of 250× coverage per base, indicating
extremely high confidence for base calls. Contigs were generated by feeding the raw genome sequence
data into the A5 pipeline (). Gene
annotations were obtained by uploading contigs to the Rapid Annotation using the Subsystem
Technology server at the National Microbial Pathogen Data Resource website (). (Individual gene sequencing data have been deposited into
GenBank. Short-read sequencing data have been deposited to the Short Read Archive (www.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?view=announcement) under accession no.
PRJNA240080.)
Mouse Infection Studies
Experiments in mice were performed according to a protocol approved by the MDACC Institutional
Animal Care and Use Committee. To induce neutropenia, we injected 5-week-old female Balb/C mice
intraperitoneally with 100 mg/kg of cyclophosphamide (Sigma, St. Louis, MO, USA) on days −4
and −1 before bacterial injection. On day 0, mice (10 per bacterial dose) were injected with
100 μL of phosphate-buffered saline (PBS) containing 10-fold increments of bacteria ranging
from 103 to 107 CFUs. As a control, 10 mice were injected with PBS alone. Mice
were monitored over 7 days for near-death status. The dose at which 50% of the mice nearly died
(hereafter referred to as LD50) was calculated by using the probit method. Neutropenia
was confirmed in select mice on postinfection days 1, 3, and 6.
Statistical Analysis
Differences between categorical variables were assessed by using the χ2 test;
Fisher exact test was used when at least 1 category had <5 occurrences. The relationship between
VGS species and Pitt bacteremia scores was analyzed by using the Mann-Whitney U test. The Bonferroni
method was employed to account for multiple comparisons when appropriate. All tests of significance
were 2-sided, and statistical significance was defined at p<0.05. SPSS
Statistics version 19 (IBM, Armonk, NY, USA ) was used for statistical analysis.
Results
Study Cohort
A total of 118 consecutive patients with VGS-positive blood cultures were included in the study
cohort; ≈80% of the patients had neutropenia and hematologic malignancies (Table 1). Most patients had bacteremia without a defined focus, but
several other clinical scenarios were observed, including skin/soft tissue infections,
gastrointestinal infections, and infective endocarditis. Most patients had clinically mild
infections (Pitt bacteremia score of 0 or 1), but 25% of patients had moderate to severe infections
(Pitt bacteremia scores of >2), including 12 patients who had VGS shock
syndrome.
Table 1
Characteristics of 118 participants in a study of Streptococcus mitis
strains causing severe clinical disease in patients with cancer*
Characteristic
No. (%)
Sex
M
64 (54)
F
54 (46)
Mean age, y (SD, range)
50 (18, 10–79)
Malignancy
70 (59)
Leukemia/myelodysplastic syndrome
20 (17)
Hematopoietic stem cell transplantation
10 (8)
Lymphoma/myeloma
18 (15)
Solid tumor
20 (17)
Neutrophils <500/μL
95 (81)
Clinical syndrome
Primary bacteremia
95 (80)
Gastrointestinal focus
8 (7)
Skin/soft tissue focus
4 (3)
Infective endocarditis
2 (2)
Clinically minor bacteremia
9 (7)
Polymicrobial infection
22 (19)
Pitt bacteremia score†‡
0
35 (37)
1
36 (38)
2
5 (5)
3
7 (7)
>4
13 (13)
Antimicrobial drug susceptibility
Penicillin
54 (46)
Ceftriaxone
107 (91)
Moxifloxacin
60 (51)
Tetracycline
69 (59)
*All patients had viridans group streptococci bacteremia. Unless otherwise noted, data are no.
(%) of patients. †Severity of infection was measured by the Pitt bacteremia score as
described (). Scores of 0 or 1 indicate
clinically mild infections; scores of >2 indicate moderate to severe
infections. ‡Determined only for patients with monomicrobial infection.
*All patients had viridans group streptococci bacteremia. Unless otherwise noted, data are no.
(%) of patients. †Severity of infection was measured by the Pitt bacteremia score as
described (). Scores of 0 or 1 indicate
clinically mild infections; scores of >2 indicate moderate to severe
infections. ‡Determined only for patients with monomicrobial infection.
VGS Species and Bacteremia
To gain insight into the species of VGS causing bacteremia in the study cohort, we performed MLSA
of 7 housekeeping genes, as described ().
Strains were assigned to species by comparing their position on the phylogenetic tree with those of
established type strains (). The 118
strains could be confidently assigned to 11 distinct species (Figure
1; Technical Appendix 1). The most commonly
observed species were S. mitis (68 strains), S. oralis (22
strains), and S. parasanguinis (12 strains). For classification purposes, various
VGS species are often placed into distinct groups; the association between VGS strains causing
bacteremia and group assignment is shown in Figure 1, using the
scheme from Sinner et al. (). In total,
80% of strains were from the Mitis group, and the remaining strains were from the Sanguinis group
(14%), Anginosus group (3%), and Salivarius group (3%).
Figure 1
Multilocus sequence analysis (MLSA) of viridans group streptococci (VGS) strains causing
bacteremia in patients with cancer. The neighbor-joining radial tree was generated by using
concatenated sequences. Strains were assigned to a particular VGS on the basis of their proximity to
type strains. Locations of well-characterized or type VGS strains (lines without circles) are also
shown for reference purposes. Five contemporaneous Streptococcus pneumoniae strains
are also included for reference purposes (shown in red). Numbers indicate bootstrap support values
(%).Scale bar indicates genetic distance. Background colors indicate VGS species group, using the
system from Sinner et al. ().
Multilocus sequence analysis (MLSA) of viridans group streptococci (VGS) strains causing
bacteremia in patients with cancer. The neighbor-joining radial tree was generated by using
concatenated sequences. Strains were assigned to a particular VGS on the basis of their proximity to
type strains. Locations of well-characterized or type VGS strains (lines without circles) are also
shown for reference purposes. Five contemporaneous Streptococcus pneumoniae strains
are also included for reference purposes (shown in red). Numbers indicate bootstrap support values
(%).Scale bar indicates genetic distance. Background colors indicate VGS species group, using the
system from Sinner et al. ().
VGS Species and Clinical Syndromes
Because of the diverse genetic nature of the various VGS species, we next tested the hypothesis
that distinct VGS species cause different clinical syndromes. Given the number of strains for each
species, we analyzed the Mitis group species (i.e., S. mitis and S.
oralis) individually and analyzed species comprising the Sanguinis, Anginosus, and
Salivarius groups by group (Table 2). Compared with strains
of other VGS species, S. mitis strains were significantly more likely to cause
primary bacteremia (p<0.01) and less likely to cause polymicrobial bacteremia (p = 0.01) and
clinically minor bacteremia (p<0.01). S. oralis strains were more likely to
cause polymicrobial infection (p = 0.02), Sanguinis group strains were more likely to cause
clinically minor bacteremia (p<0.01), and Anginosus group strains were significantly associated
with bacteremia with a gastrointestinal focus (p<0.01). When we only considered patients with
neutropenia or cases of monomicrobial bacteremia, we observed the same statistically significant
species–clinical disease relationships (data not shown).
Table 2
Association between clinical syndrome and infecting species for 118 patients with viridans
group streptococci bacteremia
Clinical syndrome
Viridans group
streptococci*
mitis
oralis
infantis/australis
Sanguinis
Anginosus
Salivarius/Vestibularis
Primary bacteremia with neutropenia
58
6
3
3
0
2
Primary bacteremia without neutropenia
1
2
0
3
0
0
Gastrointestinal focus
1
2
0
1
3
1
Skin/soft tissue focus
2
1
0
1
0
0
Infective endocarditis
0
2
0
0
0
0
Polymicrobial bacteremia
6
8
0
4
0
0
Clinically minor bacteremia
0
1
1
5
0
2
*mitis, oralis,infantis, and
australis refer to viridans group streptococci species; Sanguinis, Anginosus,
Salivarius, and Vestibularis refer to viridans streptococci groups (Figure 1) ().
*mitis, oralis,infantis, and
australis refer to viridans group streptococci species; Sanguinis, Anginosus,
Salivarius, and Vestibularis refer to viridans streptococci groups (Figure 1) ().
VGS Species and Disease Severity
We next sought to determine if there was a relationship between VGS species and disease severity
(as determined by Pitt bacteremia score). Organ dysfunction, such as hypotension, begins to occur at
Pitt bacteremia scores of >2 (). The distribution of Pitt bacteremia score by infecting species is
shown in Figure 2, panel A. Patients infected with S.
mitis were significantly more likely to have a higher Pitt bacteremia score (p<0.01).
One possible explanation for this observation is that S. mitis strains mainly
caused infections in patients with neutropenia who, compared with patients without neutropenia,
might be more likely to have serious infections. Thus, we repeated the analysis, including only
patients with neutropenia. Again, the Pitt bacteremia scores were significantly higher for patients
infected with S. mitis (p<0.01; Figure 2,
panel B). Of the 12 cases of VGS shock syndrome, 11 were caused by S. mitis strains
and 1 was caused by an S. constellatus strain (Anginosus group).
Figure 2
A) Pitt bacteremia scores for cancer patients infected with particular VGS species, showing that
more clinically severe disease is caused by Streptococcus mitis strains than other
viridans group streptococci (VGS) species. B) Pitt bacteremia scores for only those cancer patients
with neutropenia. p values refer to Mann-Whitney U comparison of Pitt bacteremia scores for patients
infected with S. mitis strains versus those infected with non–S.
mitis strains. infan., infantis; aust.,
australis; para., parasanguinis;
sang., sanguinus; angi.,
anginosus; cons., constellatus;
sali., salivarius; vest.,
vestibularis.
A) Pitt bacteremia scores for cancerpatients infected with particular VGS species, showing that
more clinically severe disease is caused by Streptococcus mitis strains than other
viridans group streptococci (VGS) species. B) Pitt bacteremia scores for only those cancerpatients
with neutropenia. p values refer to Mann-Whitney U comparison of Pitt bacteremia scores for patients
infected with S. mitis strains versus those infected with non–S.
mitis strains. infan., infantis; aust.,
australis; para., parasanguinis;
sang., sanguinus; angi.,
anginosus; cons., constellatus;
sali., salivarius; vest.,
vestibularis.
Identification of S. mitis Strain Clusters
Most cases of bacteremia and severe disease occurred in patients infected with S.
mitis; thus, we focused on S. mitis strains and strains from the closely
related S. oralis species. In contrast to what we observed for the S.
oralis strains, several distinct groupings could be visualized within the S.
mitis strains, which we arbitrarily labeled as clusters 1, 2, and 3 (Figure 3, panel A). S. mitis cluster 1 comprised 10 strains,
including 2 that were genetically identical by MLSA, and cluster 2 comprised 22 strains, including 6
that were genetically identical. Cluster 3 comprised 29 strains and may contain additional strain
groupings, but further phylogenetic delineation of this cluster could not be done with sufficient
confidence. We did not observe substantial differences, in terms of distinct disease types or
severity of infection, between patients from whom the S. mitis cluster strains were
derived (Technical Appendix 2). However, there was a
predominance of unexplained pulmonary infiltrate cases among patients infected with cluster 2
strains (p<0.01 for cluster 2 strains vs. noncluster 2 strains) (Figure 3, panel B). This variable was investigated because, given the close genetic
relationship between S. mitis and S. pneumoniae, we hypothesize
that S. mitis strains may cause pneumonia in severely immunocompromised persons
(Figure 1).
Figure 3
Multilocus sequence analysis (MLSA) and clinical correlates of Streptococcus
mitis and S. oralis strains. A) For reference purposes, the following are
labeled: viridans group streptococci (VGS) strains (SK142 for S. mitis, SK23 for
S. oralis, SK1136 for S. oligofermantans), 5 S.
pneumoniae strains, 2 S. pseudopneumoniae strains (SK674 and 103,
indicated by an asterisk), and strain SK96 (previously characterized as an S. mitis
biovar 2 strain). Numbers within the tree refer to bootstrap support values (%).B) For reference
purposes, branches of the previously labeled VGS, S. pneumoniae, and S.
pseudopneumoniae strains have been retained; however, for clarity, the branches are not
labeled. The presence or absence of unexplained pulmonary infiltrates is indicated as described in
the key. Bootstrap support values are the same as in panel A. Numbers 1–3 indicate S.
mitis clusters, and scale bars indicate genetic distances.
Multilocus sequence analysis (MLSA) and clinical correlates of Streptococcusmitis and S. oralis strains. A) For reference purposes, the following are
labeled: viridans group streptococci (VGS) strains (SK142 for S. mitis, SK23 for
S. oralis, SK1136 for S. oligofermantans), 5 S.
pneumoniae strains, 2 S. pseudopneumoniae strains (SK674 and 103,
indicated by an asterisk), and strain SK96 (previously characterized as an S. mitis
biovar 2 strain). Numbers within the tree refer to bootstrap support values (%).B) For reference
purposes, branches of the previously labeled VGS, S. pneumoniae, and S.
pseudopneumoniae strains have been retained; however, for clarity, the branches are not
labeled. The presence or absence of unexplained pulmonary infiltrates is indicated as described in
the key. Bootstrap support values are the same as in panel A. Numbers 1–3 indicate S.
mitis clusters, and scale bars indicate genetic distances.
Whole-Genome Analysis and MLSA Grouping of Strains
To determine whether the MLSA data accurately represented the entire genetic content of the Mitis
group strains, we performed whole-genome sequencing of 9 S. mitis and 1 S.
oralis isolates (Figure 4, panel A). For the 9
S. mitis strains, the reads mapped to ≈70% coverage of the only completely
finished S. mitis genome (S. mitis strain B6 []), Technical Appendix 2, Table 1). This considerable
level of intraspecies genetic diversity for S. mitis strains has been observed
previously in sequencing and DNA:DNA hybridization studies and meant that we could not use
whole-genome analysis of single-nucleotide polymorphisms to determine strain relatedness (,). Thus, we next sought to identify regions of genetic similarity among
the strains that could be analyzed for interstrain comparisons.
Figure 4
Selected data from whole-genome analysis of viridans group streptococci (VGS) strains. A)
Neighbor-joining tree generated by multilocus sequence analysis (MLSA) of Streptococcus
mitis and S. oralis strains, showing locations of VGS strains selected for
whole-genome analysis. Numbers 1–3 refer to S. mitis clusters (defined in
Figure 3). MLSA locations are also shown for the S.
mitis and S. oralis type strains (SK142 and SK23, respectively) and fully
sequenced S. mitis strain B6 and S. pneumoniae strain TIGR4. B)
SVGS004 mouse challenge data. Neighbor-joining tree of first 4 genes of the capsular polysaccharide
encoding operon (cpsA–cpsD). TIGR4 and SK142 are included
for reference purposes. Strain B6 is not included because it lacks a cps operon.
Note tight clustering of 5 VGS strains (black dots). C) Genetic arrangement surrounding the
pavA gene, which encodes a fibronectin-binding protein. Two distinct gene
arrangements are present 5′ of the pavA gene, with the arrangement for
particular strains as indicated. D) Neighbor-joining tree of LytB protein, which is involved in
cell-wall turnover, from fully sequenced S. mitis strains. Some S.
mitis strains possess a gene encoding a second LytB-like protein, which we have named LytB2
(ZP_07643922 from strain SK142). Note tight clustering of the same 5 VGS strains (black dots) for
the LytB and LytB2 proteins as was observed for the
cpsA–cpsD analysis in panel B. A, B, D) SVGS, Shelburne
VGS. Scale bars indicate genetic distances.
Selected data from whole-genome analysis of viridans group streptococci (VGS) strains. A)
Neighbor-joining tree generated by multilocus sequence analysis (MLSA) of Streptococcusmitis and S. oralis strains, showing locations of VGS strains selected for
whole-genome analysis. Numbers 1–3 refer to S. mitis clusters (defined in
Figure 3). MLSA locations are also shown for the S.
mitis and S. oralis type strains (SK142 and SK23, respectively) and fully
sequenced S. mitis strain B6 and S. pneumoniae strain TIGR4. B)
SVGS004 mouse challenge data. Neighbor-joining tree of first 4 genes of the capsular polysaccharide
encoding operon (cpsA–cpsD). TIGR4 and SK142 are included
for reference purposes. Strain B6 is not included because it lacks a cps operon.
Note tight clustering of 5 VGS strains (black dots). C) Genetic arrangement surrounding the
pavA gene, which encodes a fibronectin-binding protein. Two distinct gene
arrangements are present 5′ of the pavA gene, with the arrangement for
particular strains as indicated. D) Neighbor-joining tree of LytB protein, which is involved in
cell-wall turnover, from fully sequenced S. mitis strains. Some S.
mitis strains possess a gene encoding a second LytB-like protein, which we have named LytB2
(ZP_07643922 from strain SK142). Note tight clustering of the same 5 VGS strains (black dots) for
the LytB and LytB2 proteins as was observed for the
cpsA–cpsD analysis in panel B. A, B, D) SVGS, Shelburne
VGS. Scale bars indicate genetic distances.All 9 S. mitis strains contained operons encoding a putative polysaccharide
capsule. The first 4 genes of the operon, corresponding to
cpsA–cpsD in S. pneumoniae, were
relatively well conserved among the 9 strains. Concatenated alignment of
cpsA–cpsD showed a close relationship for the 4 cluster 2
strains and strain Shelburne VGS (SVGS) 003, whereas the
cpsA–cpsD genes from the remaining 4 strains were more
closely related to the S. pneumoniae strain TIGR4 (SVGS004 and SVGS019) or to the
S. mitis type strain SK142 (SVGS002 and SVGS011) (Figure 4, panel B).In addition to the capsule operons, multiple other comparisons arising from our whole-genome
analysis confirmed the idea that the 4 cluster 2 strains and strain SVGS003 were closely related.
All of the S. mitis strains contained the gene encoding the fibrinogen-binding
protein, PavA (pneumococcal adherence and virulence protein A). However, there was a different gene
5′ to the pavA gene in SVGS003 and the 4 cluster 2 strains than in the other
4 S. mitis strains (Figure 4, panel C). In a
similar manner, the LytB protein in cluster 2 strains and SVGS003 grouped separately from the LytB
protein in the other strains, and a LytB paralog in strain SVGS003 and the 4 cluster 2 strains was
distinct from other forms of the LytB protein and from LytB paralogs encoded by SVGS011 and SVGS019.LytB is part of a group of choline-binding proteins that are involved in cell-wall turnover, some
of which have been shown to be important for virulence in S. pneumoniae (). When the presence or absence of
choline-binding proteins was determined for the various strains, substantial strain-to-strain
heterogeneity was observed (Technical Appendix 2 Table
2). The only repeating pattern of gene content was 1 that occurred for 3 different choline-binding
protein–encoding genes: cbpE, cbpI, and lytC. These 3
genes, which are present in diverse chromosomal locations, were absent in the 4 cluster 2 strains,
SVGS003, and the S. oralis strain SVGS021 but present in the other noncluster 2
S. mitis strains. Thus, the whole-genome data support MLSA data, assigning 4 of the
fully sequenced strain to S. mitis cluster 2; strain SVGS003, a group 3 strain by
MLSA, appears to have genetic characteristics of the cluster 2 strains by whole-genome analysis.
Mouse Model for Testing VGS Virulence
Given the apparent differences in genetic content among S. mitis strains, we
sought to develop an animal model for testing VGS virulence that would approximate the disease
observed in cancerpatients with neutropenia. No neutropenia model of VGS infection exists, so we
used serial 10-fold CFU dilutions of 5 S. mitis strains to determine the
LD50 of organisms for the endpoint of being near death. The S. mitis
challenge strains included isolates from the major S. mitis clusters (Figure 5; Table 3), and we
also injected PBS as a control. None of the mice injected with PBS became ill, indicating that
neither the neutropenia nor the injection itself caused major disease (Figure 5, panel B). All of the S. mitis strains could cause near-death
status, and a dose–response relationship was observed for all strains (see example in Figure 5, panel B), but the LD50 varied by 100-fold among
the strains (Table 3). Strain SVGS016, which caused the most
severe clinical disease (i.e., it was isolated from a patient with the highest Pitt bacteremia
score) also was the most virulent in the mouse model. Thus, we suggest that S.
mitis strains cause disease in mice with neutropenia and that there is differential
virulence in this mouse model among genetically diverse S. mitis strains.
Figure 5
Streptococcus mitis strains cause dose-dependent disease in mice with
neutropenia. A) Multilocus sequence analysis–generated neighbor-joining tree showing genetic
relationships among all S. mitis strains. Bold branches indicate locations of the 5
strains used in the mouse model challenge experiment. Numbers 1–3 refer to clusters of
S. mitis strains (defined in Figure 3). Scale
bar indicates genetic distance. B) Example of mouse challenge data. Ten neutropenic Balb/C mice per
dose were infected intraperitoneally with serial 10-fold CFU dilutions of strain SVGS004 (range
107–103) and monitored for 168 h (7 d) for near-death status. Phosphate
buffered saline (PBS) was injected as a control. None of the mice injected with PBS or with the
103 dose were near death; thus, the 1 × 103 line is obscured by the PBS
line on the graph. SVGS, Shelburne viridans group streptococcus.
Table 3
Relative virulence of viridans group streptococci strains in a neutropenic mouse
model*
Strain
Streptococcus mitis cluster
Pitt bacteremia score of infected patient
LD50
SVGS004
3
1
4.1 × 105
SVGS006
2
2
1.6 × 106
SVGS016
2
1
1.4 × 105
SVGS019
1
3
1.9 × 104
SVGS031
2
1
3.6 × 105
*SVGS, Shelburne viridans group streptococcus; LD50, considered, for the purpose of
this study, to be the dose at which 50% of the animals nearly died.
Streptococcus mitis strains cause dose-dependent disease in mice with
neutropenia. A) Multilocus sequence analysis–generated neighbor-joining tree showing genetic
relationships among all S. mitis strains. Bold branches indicate locations of the 5
strains used in the mouse model challenge experiment. Numbers 1–3 refer to clusters of
S. mitis strains (defined in Figure 3). Scale
bar indicates genetic distance. B) Example of mouse challenge data. Ten neutropenic Balb/C mice per
dose were infected intraperitoneally with serial 10-fold CFU dilutions of strain SVGS004 (range
107–103) and monitored for 168 h (7 d) for near-death status. Phosphate
buffered saline (PBS) was injected as a control. None of the mice injected with PBS or with the
103 dose were near death; thus, the 1 × 103 line is obscured by the PBS
line on the graph. SVGS, Shelburne viridans group streptococcus.*SVGS, Shelburne viridans group streptococcus; LD50, considered, for the purpose of
this study, to be the dose at which 50% of the animals nearly died.
Conclusions
Since first being identified as causative agents of infections in cancerpatients with
neutropenia ≈35 years ago (), VGS
have come to be appreciated as major bacterial pathogens in patients with malignancy (,,,,). The emergence of VGS as common infectious agents has coincided with
the increasing use of prophylactic antimicrobial drugs, especially fluoroquinolones, for patients
with neutropenia (). However, despite the
clear clinical consequences of VGS infections, there is minimal understanding of their
pathophysiology.A critical first step in the study of VGS is to define the clinical syndromes caused by various
VGS species. This goal has long been hampered by difficulties in using phenotypic methods or
single-gene sequencing approaches to assign VGS strains to particular species (). Through the use of a recently developed MLSA approach (), we showed that there is a relationship
between VGS species, as defined genetically, and disease manifestations in patients with cancer
(Table 2). An unexpected finding was the relationship between
Sanguinis group strains and clinically minor bacteremia; Sanguinis group species are the leading VGS
cause of infective endocarditis and have been reported to cause virulent infections in patients with
neutropenia (,). One possible explanation for this finding is that Sanguinis
group VGS are often causative agents of transient bacteremia and that transient bacteremia
occasionally results in infective endocarditis. Platelets are thought to be critical to the
pathogenesis of VGS infective endocarditis. Thus, because of low platelet counts, persons with
cancer, especially those with hematologic malignancy, may be relatively resistant to the development
of infective endocarditis after transient VGS bacteremia ().Another key relationship that we observed was that of S. mitis and primary
bacteremia during periods of neutropenia. Our data support and extend the findings of other smaller
studies using genetic techniques that found a similar predominance of S. mitis
strains in patients with neutropenia (,,). The reason that S. mitis strains are the leading
cause of VGS bacteremia in patients with neutropenia is not known. One could postulate that
S. mitis is simply the dominant commensal VGS species and thus is the most likely
species to translocate across epithelial barriers when patients become neutropenic. Indeed, a recent
microbiome study showed that S. mitis is the predominant VGS species isolated from
buccal mucosa samples from healthy persons (). However, in our study, S. mitis not only caused the
majority of neutropenic infections but also caused a disproportionate percentage of serious
infections (Figure 2). Thus, at least for patients with
neutropenia, S. mitis is more likely than other VGS to enter into the bloodstream
and to cause serious infections once there. Moreover, compared with other VGS species, S.
mitis rarely caused clinically minor bacteremia or polymicrobial infection, suggesting that
S. mitis strains have inherently virulent properties compared with other VGS. The
data from our multistrain, whole-genome sequencing and the development of an animal model of
neutropenia and S. mitis infection should provide a key platform for elucidating
S. mitis virulence.The deep branching pattern produced by MLSA of our S. mitis strains isolated
from human blood has been observed in other investigations (,) and suggests
that the organisms currently grouped as S. mitis may more precisely be considered
as >2 species. The application of whole-genome sequencing to large numbers
of S. mitis strains will be necessary to fully resolve S. mitis
strain clusters, as shown by the somewhat discordant results of our MLSA and whole-genome analysis.
In addition, we were intrigued by the association of cluster 2 S. mitis strains and
unexplained pneumonia (Figure 3, panel B). Given the close
genetic relationship between S. mitis and S. pneumoniae, it might
be expected that some S. mitis strains could cause pneumonia, especially in
severely immunocompromised patients. Whether particular subspecies of S. mitis can
cause pneumonia is an active area of investigation in our laboratory, and if it does, that could
help explain the stubbornly low number of pathogens that can be identified for patients with
pneumonic syndromes ().This large series of invasive VGS strains includes detailed molecular and clinical information.
By combining these 2 sets of data, we have definitively established the critical role of S.
mitis strains in invasive VGS infection in patients with cancer and have laid the
groundwork for future insights into how these organisms cause serious disease in vulnerable
hosts.
Technical Appendix 1
Species assignment, clinical data, and individual gene data for viridans group streptococci
bloodstream isolates from patients with cancer.
Technical Appendix 2
Alignment of 76-bp, paired-end reads for viridans group streptococci (VGS) strains with
Streptococcus mitis and S. pneumoniae reference genomes,
choline-binding proteins among sequenced VGS strains and S. pneumoniae strain
TIGR4, and multilocus sequence analysis and clinical correlates of S.
mitis and S. oralis strains.
Authors: L N Ikryannikova; K N Lapin; M V Malakhova; A V Filimonova; E N Ilina; V A Dubovickaya; S V Sidorenko; V M Govorun Journal: Infect Genet Evol Date: 2011-07-21 Impact factor: 3.342
Authors: Cynthia J Bishop; David M Aanensen; Gregory E Jordan; Mogens Kilian; William P Hanage; Brian G Spratt Journal: BMC Biol Date: 2009-01-26 Impact factor: 7.431
Authors: Daniel M Musher; Ingrid L Roig; Guillermo Cazares; Charles E Stager; Nancy Logan; Hossam Safar Journal: J Infect Date: 2013-03-19 Impact factor: 6.072
Authors: J Radocha; P Paterová; A Zavřelová; B Víšek; F Gabalec; H Žemličková; P Žák Journal: Folia Microbiol (Praha) Date: 2017-08-03 Impact factor: 2.099
Authors: C Garcia-de-la-Maria; Y Q Xiong; J M Pericas; Y Armero; A Moreno; N N Mishra; M J Rybak; T T Tran; C A Arias; P M Sullam; A S Bayer; J M Miro Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Kathryn M Emmer; Natalie A Celeste; Willie A Bidot; Marcel I Perret-Gentil; Raphael A Malbrue Journal: J Am Assoc Lab Anim Sci Date: 2019-02-27 Impact factor: 1.232
Authors: Anthony R Flores; Jessica Galloway-Peña; Pranoti Sahasrabhojane; Miguel Saldaña; Hui Yao; Xiaoping Su; Nadim J Ajami; Michael E Holder; Joseph F Petrosino; Erika Thompson; Immaculada Margarit Y Ros; Roberto Rosini; Guido Grandi; Nicola Horstmann; Sarah Teatero; Allison McGeer; Nahuel Fittipaldi; Rino Rappuoli; Carol J Baker; Samuel A Shelburne Journal: Proc Natl Acad Sci U S A Date: 2015-05-04 Impact factor: 11.205
Authors: Nagendra N Mishra; Truc T Tran; Ravin Seepersaud; Cristina Garcia-de-la-Maria; Kym Faull; Alex Yoon; Richard Proctor; Jose M Miro; Michael J Rybak; Arnold S Bayer; Cesar A Arias; Paul M Sullam Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191